<p>Delphi Financial Group Inc.在第一季度根據最新提交給美國證券交易委員會的 13F 報告，購買了 Cartesian Therapeutics, Inc.（NASDAQ:RNAC - Free Report）的新頭寸。該公司購買了公司股票的 660,852 股，價值約 430,000 美元。Cartesian Therapeutics 佔 Delphi Financial Group Inc.投資組合的 0.3%，是其第 23 大持倉。截至最近一次提交的美國證券交易委員會報告，Delphi Financial Group Inc.擁有 Cartesian Therapeutics 約 12.26% 的股份。</p>
<p>獲取 <strong>Cartesian Therapeutics</strong> 警報：</p>
<p>另外，Hall Laurie J Trustee 在第一季度購買了 Cartesian Therapeutics 的新股份，價值約 34,000 美元。機構投資者和對沖基金擁有公司股票的 86.95%。</p>
<h2>Cartesian Therapeutics 股價下跌 0.2%</h2>
<p>NASDAQ RNAC 股票週二交易中下跌 0.04 美元，報 16.78 美元。該公司的交易量為 399,320 股，相比平均交易量 88,681 股。Cartesian Therapeutics, Inc.的 12 個月最低價為 11.66 美元，最高價為 42.60 美元。該公司的 50 天移動平均價為 25.75 美元，200 天移動平均價為 22.34 美元。</p>
<p>Cartesian Therapeutics（NASDAQ:RNAC - 獲取免費報告）最近公佈了其截至 5 月 8 日的財報。該公司報告本季度每股虧損 1.97 美元，超過分析師預期的每股虧損 0.81 美元。該季度公司營收為 584 萬美元。作為一個團隊，股票分析師預測 Cartesian Therapeutics, Inc.本財年將實現 2.28 美元的每股收益。</p>
<h2>華爾街分析師觀點</h2>
<p>一些研究公司對 RNAC 發表了意見。Oppenheimer 在 7 月 2 日的報告中將 Cartesian Therapeutics 的評級從 “表現優異” 降至 “市場表現”。Mizuho 在 5 月 24 日的研究報告中對 Cartesian Therapeutics 進行了覆蓋。他們給出了 “買入” 評級和 40.00 美元的價格目標。Leerink Partnrs 在 4 月 23 日的研究報告中重申了對 Cartesian Therapeutics 股票的 “表現優異” 評級。SVB Leerink 在 4 月 23 日的報告中對 Cartesian Therapeutics 進行了覆蓋。他們給出了 “表現優異” 評級和 39.00 美元的目標價。最後，Needham &amp; Company LLC 在週一的報告中重申了對 Cartesian Therapeutics 股票的 “買入” 評級，並給出了 42.00 美元的價格目標。一位投資分析師對該股票進行了持有評級，六位分析師對該公司股票給出了買入評級。根據 MarketBeat.com 的數據，Cartesian Therapeutics 的平均評級為 “中度買入”，共識目標價為 43.83 美元。</p>
<p><strong>查看我們關於 RNAC 的最新股票報告</strong></p>
<h2>Cartesian Therapeutics 簡介（免費報告）</h2>
<p>Cartesian Therapeutics, Inc.是一家臨牀階段的生物技術公司，致力於提供用於治療自身免疫疾病的 mRNA 細胞療法。該公司正在開發 Descartes-08，一種自體抗 BCMA RNA 工程嵌合抗原受體 T 細胞療法，目前正在進行第 2b 期臨牀開發，用於治療全身性重症肌無力，以及用於其他自身免疫疾病的骨髓瘤自動免疫籃試驗患者。</p>
<h2>參見</h2>
<ul>
<li>我們喜歡的五隻股票，比 Cartesian Therapeutics 更好</li>
<li>如何最有效地使用 MarketBeat 盈利篩選器</li>
<li>3 只內部買入股票，現在加入您的觀察名單</li>
<li>如何找到被低估的股票</li>
<li>Commvault 股票：AI 網絡安全巨頭準備再次翻倍</li>
<li>什麼是債券市場假日？如何投資和交易</li>
<li>Intuit 股票準備飆升：RBC 看到 GenAI 帶來巨大上漲</li>
</ul>
<p><em>此即時新聞警報由敍事科技和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 賺取 1129% 利潤的交易員公佈新的人工智能（來自紀念碑交易聯盟）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzAy"/></p>
<h2>您現在是否應該投資 1,000 美元購買 Cartesian Therapeutics？</h2>
<p>在考慮購買 Cartesian Therapeutics 之前，您需要聽到這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Cartesian Therapeutics 不在名單上。</p>
<p>儘管 Cartesian Therapeutics 目前在分析師中有 “中度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

RNAC

<p>Delphi Financial Group Inc. 已經在 Cartesian Therapeutics, Inc. 中獲得了新的持倉。該公司購買了該公司價值約 $430,000 的 660,852 股股票。Cartesian Therapeutics 是一家臨牀階段的生物技術公司，致力於開發用於自身免疫性疾病的 mRNA 細胞療法。該股票的 12 個月最低價為 $11.66，最高價為 $42.60</p>

<p>Delphi Financial Group Inc. purchased a new position in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 660,852 shares of the company's stock, valued at approximately $430,000. Cartesian Therapeutics comprises 0.3% of Delphi Financial Group Inc.'s investment portfolio, making the stock its 23rd biggest holding. Delphi Financial Group Inc. owned about 12.26% of Cartesian Therapeutics as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Delphi Financial Group Inc.在第一季度根據最新提交給美國證券交易委員會的 13F 報告，購買了 Cartesian Therapeutics, Inc.（NASDAQ:RNAC - Free Report）的新頭寸。該公司購買了公司股票的 660,852 股，價值約 430,000 美元。Cartesian Therapeutics 佔 Delphi Financial Group Inc.投資組合的 0.3%，是其第 23 大持倉。截至最近一次提交的美國證券交易委員會報告，Delphi Financial Group Inc.擁有 Cartesian Therapeutics 約 12.26% 的股份。</p>
</div><p>Get <strong>Cartesian Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cartesian Therapeutics</strong> 警報：</p>
</div><p>Separately, Hall Laurie J Trustee bought a new stake in Cartesian Therapeutics in the 1st quarter valued at about $34,000. Institutional investors and hedge funds own 86.95% of the company's stock.</p>
<div class="lb-trans"><p>另外，Hall Laurie J Trustee 在第一季度購買了 Cartesian Therapeutics 的新股份，價值約 34,000 美元。機構投資者和對沖基金擁有公司股票的 86.95%。</p>
</div><h2>Cartesian Therapeutics Trading Down 0.2 %</h2>
<div class="lb-trans"><h2>Cartesian Therapeutics 股價下跌 0.2%</h2>
</div><p>Shares of NASDAQ RNAC traded down $0.04 during trading on Tuesday, reaching $16.78. The company had a trading volume of 399,320 shares, compared to its average volume of 88,681. Cartesian Therapeutics, Inc. has a 12-month low of $11.66 and a 12-month high of $42.60. The business's 50-day moving average is $25.75 and its 200 day moving average is $22.34.</p>
<div class="lb-trans"><p>NASDAQ RNAC 股票週二交易中下跌 0.04 美元，報 16.78 美元。該公司的交易量為 399,320 股，相比平均交易量 88,681 股。Cartesian Therapeutics, Inc.的 12 個月最低價為 11.66 美元，最高價為 42.60 美元。該公司的 50 天移動平均價為 25.75 美元，200 天移動平均價為 22.34 美元。</p>
</div><p>Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($1.97) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($1.16). The firm had revenue of $5.84 million during the quarter. As a group, equities analysts forecast that Cartesian Therapeutics, Inc. will post 2.28 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cartesian Therapeutics（NASDAQ:RNAC - 獲取免費報告）最近公佈了其截至 5 月 8 日的財報。該公司報告本季度每股虧損 1.97 美元，超過分析師預期的每股虧損 0.81 美元。該季度公司營收為 584 萬美元。作為一個團隊，股票分析師預測 Cartesian Therapeutics, Inc.本財年將實現 2.28 美元的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of research firms have weighed in on RNAC. Oppenheimer lowered Cartesian Therapeutics from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Tuesday, July 2nd. Mizuho assumed coverage on Cartesian Therapeutics in a research report on Friday, May 24th. They issued a &#34;buy&#34; rating and a $40.00 price objective for the company. Leerink Partnrs reiterated an &#34;outperform&#34; rating on shares of Cartesian Therapeutics in a research report on Tuesday, April 23rd. SVB Leerink assumed coverage on Cartesian Therapeutics in a report on Tuesday, April 23rd. They set an &#34;outperform&#34; rating and a $39.00 target price for the company. Finally, Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $42.00 price objective on shares of Cartesian Therapeutics in a report on Monday. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, Cartesian Therapeutics has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $43.83.</p>
<div class="lb-trans"><p>一些研究公司對 RNAC 發表了意見。Oppenheimer 在 7 月 2 日的報告中將 Cartesian Therapeutics 的評級從 “表現優異” 降至 “市場表現”。Mizuho 在 5 月 24 日的研究報告中對 Cartesian Therapeutics 進行了覆蓋。他們給出了 “買入” 評級和 40.00 美元的價格目標。Leerink Partnrs 在 4 月 23 日的研究報告中重申了對 Cartesian Therapeutics 股票的 “表現優異” 評級。SVB Leerink 在 4 月 23 日的報告中對 Cartesian Therapeutics 進行了覆蓋。他們給出了 “表現優異” 評級和 39.00 美元的目標價。最後，Needham &amp; Company LLC 在週一的報告中重申了對 Cartesian Therapeutics 股票的 “買入” 評級，並給出了 42.00 美元的價格目標。一位投資分析師對該股票進行了持有評級，六位分析師對該公司股票給出了買入評級。根據 MarketBeat.com 的數據，Cartesian Therapeutics 的平均評級為 “中度買入”，共識目標價為 43.83 美元。</p>
</div><p><strong>View Our Latest Stock Report on RNAC</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 RNAC 的最新股票報告</strong></p>
</div><h2>Cartesian Therapeutics Profile (Free Report)</h2>
<div class="lb-trans"><h2>Cartesian Therapeutics 簡介（免費報告）</h2>
</div><p>Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.</p>
<div class="lb-trans"><p>Cartesian Therapeutics, Inc.是一家臨牀階段的生物技術公司，致力於提供用於治療自身免疫疾病的 mRNA 細胞療法。該公司正在開發 Descartes-08，一種自體抗 BCMA RNA 工程嵌合抗原受體 T 細胞療法，目前正在進行第 2b 期臨牀開發，用於治療全身性重症肌無力，以及用於其他自身免疫疾病的骨髓瘤自動免疫籃試驗患者。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Cartesian Therapeutics</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>3 Insider-Buy Stocks to Add to Your Watchlist Now</li>
<li>How to Find Undervalued Stocks</li>
<li>Commvault Stock: AI Cybersecurity Giant Ready to Double Again</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Intuit Stock Ready to Soar: RBC Sees Big Upside with GenAI</li>
</ul>
<div class="lb-trans"><h2>參見</h2>
<ul>
<li>我們喜歡的五隻股票，比 Cartesian Therapeutics 更好</li>
<li>如何最有效地使用 MarketBeat 盈利篩選器</li>
<li>3 只內部買入股票，現在加入您的觀察名單</li>
<li>如何找到被低估的股票</li>
<li>Commvault 股票：AI 網絡安全巨頭準備再次翻倍</li>
<li>什麼是債券市場假日？如何投資和交易</li>
<li>Intuit 股票準備飆升：RBC 看到 GenAI 帶來巨大上漲</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科技和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Trader behind 1,129% profit reveals new AI (From Monument Traders Alliance)(Ad)</p>
<div class="lb-trans"><p>→ 賺取 1129% 利潤的交易員公佈新的人工智能（來自紀念碑交易聯盟）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzAy" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8702&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Cartesian Therapeutics right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1,000 美元購買 Cartesian Therapeutics？</h2>
</div><p>Before you consider Cartesian Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買 Cartesian Therapeutics 之前，您需要聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Cartesian Therapeutics 不在名單上。</p>
</div><p>While Cartesian Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Cartesian Therapeutics 目前在分析師中有 “中度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

德爾菲金融集團公司收購了 Cartesian Therapeutics, Inc.（納斯達克：RNAC）的新股份